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sites was prescribed. No upstaging of low risk patients to a 
higher risk was observed. 
Conclusions: Our results have shown that Cho-PET seem to 
be a promising diagnostic tool in prostate cancer patients 
who are candidates to radical radiotherapy and supporting 
the decision making in treatment planning, in particular in 
intermediate-high risk. Although a simultaneous integrated 
boost on Cho-PET positive sites is still under investigation, it 
could be a possible option to intensify local radiation 
treatment in this setting. 
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Purpose/Objective: Endorectal balloons (ERBs) can be used 
for the stabilisation of the prostate during radical external 
beam radiotherapy (EBRT). By reducing positional 
uncertainties, the internal margin may be decreased, 
reducing overall PTV volume. Studies have demonstrated 
reduced prostate motion, but the effect of ERBs on the 
seminal vesicles (SV) is less well reported. We aim to quantify 
ERB effect on seminal vesicle positioning.  
Materials and Methods: Eight consecutive patients were 
chosen from a local prospective study into the feasibility of 
using ERBs in prostate EBRT practice. Patients eligible for the 
study were those undergoing radical EBRT as their primary 
treatment modality for localised prostate cancer. Planning 
scans were performed supine, bladder empty, with and 
without a 100cc air filled RectalPro ERB. Contouring was 
undertaken using Pinnacle (Version 9.6). The maximum A-P 
overlap between rectum and seminal vesicle was measured as 
distance from anterior rectal wall to posterior extent of SV 
(see Figure 1 for technique). This was measured for left and 
right SVs then averaged. Maximum lateral spread of seminal 
vesicles was measured on the slice demonstrating maximum 
distance between the lateral edges of the left and right 
seminal vesicles. Superior-inferior SV extent was measured 
from base to tip of seminal vesicles and averaged between 
left and right sides. Two-tailed, paired Student's T-tests were 
used to compare the ERB and no-ERB data. 
Results: Maximum A-P overlap of the SV and rectum was 
significantly greater with an ERB in-situ than without (Mean: 
1.78cm versus 0.65cm, p<0.001). Maximum lateral separation 
of the SV was significantly greater with an ERB in-situ than 
without (Mean: 6.69cm versus 6.34cm, p=0.019). Superior-
inferior extent of SVs was significantly greater with ERB in-
situ (Mean: 2.6cm versus 2.0cm, p=0.0014). SV volumes were 
not significantly affected by ERB presence. 
Conclusions: One perceived benefit of ERB use in prostate 
radiotherapy is reducing rectal dosage. This is by firstly 
enabling a smaller PTV and secondly by pushing posterior 
rectum further from the high dose field. For intermediate or 
high risk patients who require full SV treatment this benefit 
may be negated by unfavourable positioning of the SV 
relative to the rectum. Here we show that the presence of an 
ERB causes increased lateral and superior-inferior spread of 
the SV, along with increased A-P overlap with the rectum. 
These previously undescribed anatomical alterations may 
influence planning of intermediate and high risk prostate 
cancer patients with ERB in-situ. Specifically, we hypothesise 
that increased A-P overlap may limit sparing of the posterior 
rectum when undertaking full length seminal vesicle 
irradiation. An on-going planning study at our institution will 
investigate this hypothesis. 
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Purpose/Objective: The rate of biochemical failure after 
primary external-beam radiation therapy (EBRT) in prostate 
cancer is still not negligible, around 33%. Management of 
prostate cancer relapses after EBRT is still undefined. Re-
irradiation schedules have been explored in different tumor 
sites. In this report, we present our preliminary experience of 
re-irradiation using SBRT for localized prostate cancer 
failure. 
Materials and Methods: Between March 2011 and April 2014, 
robotic SBRT was administered to patients previously treated 
with external-beam radiation therapy to a median dose of 72 
Gy (range, 45–76.5Gy) and with biochemical failure 
corresponding to a local in-field recurrence of prostate 
cancer. All patients underwent a pelvis MRI to confirm the 
recurrence and a total body staging using a 18F-choline 
positron emission tomography. The prescription dose 
consisted of five fractions of 7.25 Gy to a total dose of 36.25 
Gy. Efficacy was evaluated based on biochemical response 
and toxicity was evaluated according to CTCAE v.4.0 
questionnaires and International Prostate Symptom Score. 
Results: Seventeen patients were treated (five urethrovesical 
anastomosis lesions, nine lesions within the prostate, and 
three in residual seminal vesicles) and followed for a median 
6 months (mean, 9.4 months, range, 2.5–39.4 months). 
Median time between the first EBRT of prostate cancer and 
the first day of CyberKnife® treatment was 123 months 
(range, 38–398 months). A biochemical response was 
observed in 16 of the 17 evaluable patients (94.1%) and no in-
field progression was reported. Only one patient had a 
biochemical failure 5 months after the treatment, correlating 
to metastatic progression without evidence of local 
recurrence. Treatment was well tolerated, with five cases of 
genitourinary or gastrointestinal acute grade 1 toxicities . No 
grade ≥ 2 or other acute toxicities were reported. 
Conclusions: Stereotactic Body Re-irradiation Therapy using 
CyberKnife® after failed EBRT showed favorable results in 
terms of in-field local and biochemical control. Toxicity was 
low and acceptable. Further prospective studies are needed 
to confirm these results to select patient and to evaluate the 
introduction of androgen deprivation therapy. 
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Purpose/Objective: To evaluate the therapeutic outcomes of 
short course neoadjuvant and concurrent androgen-
deprivation therapy (ADT) and intensity-modulated radiation 
therapy (IMRT) with fiducial gold markers for intermediate 
and high-risk prostate cancer.  
Materials and Methods: This is a retrospective study of 325 
patients with intermediate or high-risk prostate cancer 
according to the National Comprehensive Cancer Network 
guidelines who underwent ADT(neoadjuvant :4-8months 
,concurrent:2months) and IMRT (76 Gy) with gold marker 
implantation between 2001 and 2010. 
Results: Five-year distant metastasis-free survival was 
significantly lower for super high-risk patients compared with 
intermediate and high-risk patients (82.6% vs. 99.4% and 
96.5%, respectively; p < 0.01). The 5-year biochemical 
relapse-free survival rates significantly declined with 
increasing prostate cancer risk (p < 0.01) and were 95.9%, 
87.2%, and 73.1% for the intermediate-risk, high-risk, and 
super high-risk patients, respectively. With multivariate 
analysis identified high pretreatment PSA level (³ 20 ng/ml) 
and Gleason sum ³ 8 as significant risk factors for recurrence 
and the duration of ADT was not statistically significant 
defference in BRFS in each risk group. Acute genitourinary 
and gastrointestinal toxicity grade ≥3 were not observed in 
any of the patients. Late grade 3 genitourinary toxicity 
occurred in 0.3% of patients. 
Conclusions: Short course ADT with 76-Gy IMRT using fiducial 
gold markers resulted in good therapeutic outcomes with few 
serious complications in patients with intermediate and high-
risk prostate cancer except super high risk group. More 
intensive therapy might be necessary for super high risk 
group. 
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Purpose/Objective: Previous clinical phase I/II trials have 
confirmed that radiotherapy (RT) in combination with 
regional hyperthermia (HT) is promising and feasible without 
severe toxicity in patients with prostate cancer. We 
hypothesized the positive relationships between the clinical 
outcomes and thermal parameters. The purpose of our study 
was to assess the efficacy of RT combined with regional HT 
and the potential contribution of regional HT with higher 
thermal parameters to the clinical outcomes in patients with 
high-risk prostate cancer. 
Materials and Methods: According to our institution’s 
treatment protocol, HT was combined with RT to improve the 
clinical outcomes in selected patients with high-risk prostate 
cancer. Eighty-two patients treated with RT plus HT and 64 
patients treated with RT alone were retrospectively 
analyzed. The primary reasons for non-indication of HT were 
as follows: obesity: n=20, an advanced age: n=12, patient 
refusal: n=8, cardiac disease: n=6, and others: n=18. All 
patients were treated with 3D-CRT in 70 Gy at 35 fractions 
with the exception of nine patients. HT using an 8-MHz 
radiofrequency-capacitive heating device was applied 
immediately after RT once or twice a week. The median 
duration of heating was 50 minutes (range, 30-50) in one 
heating session. The median number of heating sessions 
ranged from two to six (median 5). All patients initially 
underwent neoadjuvant androgen deprivation therapy (ADT) 
(median, 9 months); adjuvant ADT was continued in 20 
patients after the completion of RT (median, 5 months). 
Univariate and multivariate analyses were performed using 
several factors including thermal parameters to identify 
prognostic factors for the biochemical disease-free survival 
(bDFS). 
Results: The median follow-up duration was 61 months. The 
five-year bDFS rate in 82 patients treated with RT plus HT 
was 78%, while that in 64 patients treated with RT alone was 
72%; the difference was not significant. Among 75 patients 
treated with RT plus HT with intra-rectal temperature 
measurements, higher thermal parameters were significant 
prognostic factors for the bDFS in the univariate analyses. A 
higher thermal parameter of CEM43?T90 (≥ 1 minute) and a T 
stage of T1-2 were significant prognostic factors according to 
the multivariate analysis. The five-year bDFS rates for the 40 
patients with a higher CEM43?T90 and 64 patients treated 
with RT alone were significantly different, whereas those for 
the 35 patients with a lower CEM43?T90 and 64 patients 
treated with RT alone were not. A significant negative 
correlations was observed between the CEM43?T90 and the 
thickness of the maximum ventral subcutaneous fat in the 
pelvic region. 
Conclusions: The addition of HT with higher thermal 
parameters to RT may improve the bDFS in patients with 
high-risk prostate cancer. The findings also indicate the 
importance of the careful selection of treatable patients with 
higher thermal parameters.  
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Purpose/Objective: We report the toxicity and clinical 
outcome for prostate dose-painting radiotherapy with 
moderate hypo-fractionation (dose to prostate 60Gy in 20 
fractions, integrated boost dose 66-68Gy in 20 fractions); 
